Nurix Therapeutics Inc (NASDAQ: NRIX) on Tuesday, soared 26.67% from the previous trading day ,before settling in for the closing price of $13.80. Within the past 52 weeks, NRIX’s price has moved between $4.22 and $16.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 27.29%. The company achieved an average annual earnings per share of -20.21%. With a float of $45.03 million, this company’s outstanding shares have now reached $48.72 million.
Considering the fact that the conglomerate employs 284 people, you should pay attention to its efficiency factor.
Nurix Therapeutics Inc (NRIX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nurix Therapeutics Inc is 7.90%, while institutional ownership is 89.09%. The most recent insider transaction that took place on Feb 16 ’24, was worth 68,223. In this transaction Chief Financial Officer of this company sold 6,812 shares at a rate of $10.02, taking the stock ownership to the 68,333 shares. Before that another transaction happened on Jan 30 ’24, when Company’s Chief Scientific Officer sold 2,334 for $7.99, making the entire transaction worth $18,649. This insider now owns 36,402 shares in total.
Nurix Therapeutics Inc (NRIX) Earnings and Forecasts
As on 11/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.77 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.57) by -$0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.21% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Nurix Therapeutics Inc (NRIX) is currently performing well based on its current performance indicators. A quick ratio of 3.40 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.65, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Compared to the last year’s volume of 0.82 million, its volume of 0.9 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 63.97%. Additionally, its Average True Range was 1.26.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 99.75%, which indicates a significant increase from 99.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.13% in the past 14 days, which was higher than the 83.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.96, while its 200-day Moving Average is $9.13. Nevertheless, the first resistance level for the watch stands at $18.72 in the near term. At $19.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.42. If the price goes on to break the first support level at $15.02, it is likely to go to the next support level at $12.57. Should the price break the second support level, the third support level stands at $11.32.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
Market capitalization of the company is 854.60 million based on 49,151K outstanding shares. Right now, sales total 76,990 K and income totals -143,950 K. The company made 15,160 K in profit during its latest quarter, and -41,960 K in sales during its previous quarter.
